Scrip - Pharma News And Expert Analysis For Commercial Decision Makers since 1972

Multinationals Return To Growth In China In First Half

Aug 14 2023

AZ and Novo Nordisk reported sales growth from innovative new drugs in China, despite the lingering impact of the country's volume-based procurement scheme. Meanwhile, Novartis, Sanofi and Roche saw gains for new antibody and cancer drugs, along with solid vaccine sales.

Embracing China’s Brave New Pharmaceutical World!

Dec 05 2025

• By Ellon Xu, Philip Leung, and Grace Shieh

Already one of the world’s largest pharmaceutical markets, China has tremendous growth potential, but significant policy and market changes are rocking the basis of competition. Multinational biopharma corporations cannot succeed in this new environment unless they fundamentally reinvent their business models to adapt to sweeping change.

Scrip - Pharma News And Expert Analysis For Commercial Decision Makers since 1972

Scrip Data Article Without An Author

Article Without An Author Listed

Leqembi Approval Opens Door To Alzheimer’s Market For Lilly And Others

Brii Ups Its Bet On VBI’s Hepatitis B Assets Amid Larger Treatment, Prevention Push

Spotlight

Multinationals Return To Growth In China In First Half

Interviews

Data

Focus On Asia

Embracing China’s Brave New Pharmaceutical World!

R&D

Business

Scrip Originals